US9629852B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9629852-B2 |
| Application number | US-60142908-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 15, 2008 |
| Priority date | Oct 16, 2007 |
| Publication date | Apr 25, 2017 |
| Grant date | Apr 25, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle.
Opening claim text (preview).
We claim: 1. A pharmaceutical composition suitable for ophthalmic use comprising 0.005% w/v latanoprost or a pharmaceutically acceptable salt therof, 0.15% w/v castor oil, 0.2 to 0.75% w/v of polyethylene glycol hydroxystearate, a co-solvent, a chelating agent, a preservative, and pharmaceutically acceptable vehicle, wherein the ratio of oil to polyethylene glycol hydroxystearate is less than 1.0, wherein the composition is in the form of a self-emulsifying micro-emulsion with average droplet size of about 100 nm or less and a zeta potential between −0.1 mV to −20 mV, wherein the composition does not comprise a cationic surfactant, and wherein the composition does not comprise a quaternary ammonium compound. 2. The pharmaceutical composition as claimed in claim 1 Wherein the emulsion has an average droplet size of less than 100 nanometers in diameter. 3. The pharmaceutical composition as claimed in claim 2 , wherein the emulsion has a percent transmission greater than 70%. 4. The pharmaceutical composition as claimed in claim 2 , wherein the emulsion has a percent transmission greater than 80%. 5. The pharmaceutical composition as claimed in claim 1 wherein the composition does not show any clinical sign of ocular irritation when tested in rabbits.
Medicinal preparations containing organic active ingredients · CPC title
Drugs for disorders of the senses · CPC title
Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence) · CPC title
Eye, e.g. artificial tears · CPC title
Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.